Percardia CEO to Speak at Venture One Summit 2002 "Best of Breed in Venture Capital"
Merrimack, NH, March 14, 2002 /PRNewswire/ -- Percardia Inc., a venture-backed, early stage medical device company developing new and novel therapeutic interventions for the treatment of coronary artery disease, announced today that its CEO, Ms. Nancy Briefs, will speak at the prestigious VentureOne Summit "Best of Breed in Venture Capital", March 19-20 at The Four Seasons Hotel in San Francisco (see www.ventureone.com for more information).
The VentureOne Summit is considered a premiere event in the venture capital industry. The event showcases sixty of the nation's most promising start-ups to an audience of leading venture capitalists, corporate investors and service providers. Ms. Briefs remarked, "We are very pleased that Percardia was selected to present at such a prestigious event. Also, we are extremely proud of the fact that a number of our investors (Advanced Technology Ventures, Atlas Venture, Crescendo Ventures and Vanguard Venture Partners) are Advisors to the meeting."
VentureOne was founded in 1987 to promote the financing and growth of entrepreneurial companies and is now the leading provider of information to the nation's most important and influential venture capital firms. In addition, VentureOne's online database, VentureSource, provides real-time financing information on more than 10,000 venture-backed companies. A significant number of top-tier venture capital firms refer to this database to proactively identify their next investment candidates.
Percardia Inc., founded in 1998, has raised $32 million to date and employs 25 people. The company is currently developing the VSTENT Myocardial Implant, a cardiovascular implant designed to treat patients with coronary artery disease. Percardia's novel approach to coronary revascularization could address a $1.5 billion market.
Additional information regarding the Company and its technology can be obtained at the company's website www.percardia.com.